[2-(4-ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid | 1159507-43-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: [2-(4-ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid
• 英文别名: [2-(4-Ethylimidazol-1-yl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
• CAS: 1159507-43-3
• 化学式: C₇H₁₄N₂O₇P₂
• 分子量: 300.145
• InChiKey: PCRKDKXHZZDFGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (4-ethyl-imidazol-1-yl)-acetic acid 在 亚磷酸 、 三氯氧磷 、 盐酸 作用下， 以 甲苯 、 水 为溶剂， 反应 19.0h， 生成 [2-(4-ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid
  参考文献：
  名称：

  C2-C5-Alkyl-Imidazole-Bisphosphonates

  摘要：

  本文描述了C2-C5-烷基取代的[(咪唑-1-基)-1-羟基-1-膦酸乙基]-膦酸类化合物的制备方法或工艺，以及它们在制备药物配方、治疗疾病、治疗疾病的使用方法、包括它们和/或化合物的药物配方在内的药物配方的用途。这些化合物能够抑制过度或不适当的骨吸收，并用于治疗其他由于靶蛋白质的过度异戊烷化而引起的疾病，例如Hutchinson-Gilford晚年型症候群。这些化合物的化学式为I，其中R1和R2中的一个是氢，另一个是分支或非分支的C2-C5-烷基，可以是自由形式、酯形式和/或盐形式。

  公开号：

  US20090143337A1

文献信息

• PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE
  申请人：Beltz Karen

  公开号：US20110034418A1

  公开（公告）日：2011-02-10

  The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers, to poorly water-soluble salts of such bisphosphonates, to crystalline forms of the free compounds and the salts and to other related aspects, where the compounds are of the Formula (I), where R 1 and R 2 are as described in the specification. Compounds of the Formula (I) and their forms mentioned in the disclosure are useful for the treatment of bone-related disorders and cancer.

  本发明涉及包含一种难溶性双磷酸盐及一种或多种生物相容性聚合物的储存型制剂，以及这种双磷酸盐的难溶性盐、自由化合物和盐的结晶形式，以及其他相关方面。其中，化合物为式(I)，其中R1和R2如说明书所述。在本文中提到的式(I)化合物及其形式对于治疗与骨有关的疾病和癌症具有用处。
• US7977323B2
  申请人：——

  公开号：US7977323B2

  公开（公告）日：2011-07-12
• [EN] C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES<br/>[FR] (ALKYL EN C2-C5)IMIDAZOLE-BISPHOSPHONATES
  申请人：NOVARTIS AG

  公开号：WO2009068567A1

  公开（公告）日：2009-06-04

  C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
• [EN] PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE<br/>[FR] COMPOSITION PHARMACEUTIQUE AVEC DU BISPHOSPHONATE
  申请人：NOVARTIS AG

  公开号：WO2009121935A2

  公开（公告）日：2009-10-08

  The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers, to poorly water-soluble salts of such bisphosphonates, to crystalline forms of the free compounds and the salts and to other related aspects, where the compounds are of the Formula (I), where R1 and R2 are as described in the specification. Compounds of the Formula (I) and their forms mentioned in the disclosure are useful for the treatment of bone-related disorders and cancer.